Does Zepbound Lower Blood Pressure?

Yes — in the trials that measured it carefully, tirzepatide (the active drug in Zepbound and Mounjaro) lowered blood pressure, and by a clinically meaningful amount. But that headline needs two immediate qualifiers: the drug is not approved to treat hypertension, and the people who fell most in the trials were not being treated for high blood pressure. This page walks through what the evidence actually shows, how big the effect is, and why it does not mean you should stop your blood-pressure medication.

The single sentence to anchor on: tirzepatide reliably nudges blood pressure down as a side benefit of the weight loss and metabolic change it drives — but it is a weight-management drug, not a blood-pressure drug, and the change is not a reason to self-manage hypertension.

What the best data shows: the SURMOUNT-1 blood-pressure substudy

Most weight-loss trials measure blood pressure with a single cuff reading at a clinic visit, which is noisy. SURMOUNT-1 — tirzepatide's pivotal obesity trial — did something more rigorous for a subgroup: a prospectively planned ambulatory blood pressure monitoring (ABPM) substudy, where a wearable cuff records blood pressure automatically across a full 24 hours, day and night¹. That is the gold-standard way to capture a drug's real effect on blood pressure, and it is the strongest evidence we have on this question.

The result was clear. Against placebo, tirzepatide lowered 24-hour systolic blood pressure at every dose after 36 weeks¹:

Those are placebo-adjusted reductions of roughly 7 to 11 mm Hg in 24-hour systolic pressure — a drop in the same ballpark as adding a standard blood-pressure pill, achieved here as a byproduct of a weight-loss drug. Reductions were consistent across both daytime and nighttime readings, and diastolic (the lower number) fell modestly too, by about 2 to 3 mm Hg at the lower doses¹. For context on how much weight was driving this, see what Zepbound weight-loss results actually look like over a full course.

One detail matters for honesty: the people in this substudy started with an average 24-hour systolic pressure of about 125 mm Hg — i.e. they were, on average, normotensive (participants had to have office blood pressure below 140/90 to enrol, though many were on stable blood-pressure medication)¹. So this is not a study of tirzepatide "curing" high blood pressure. It shows that in adults with obesity, tirzepatide shifts blood pressure downward — which is favorable, but is a different claim from "it treats hypertension."

Why does a weight-loss drug lower blood pressure?

Two overlapping mechanisms explain it, and the distinction matters for how durable the effect is.

Weight loss itself. Losing a substantial amount of body weight lowers blood pressure — this is one of the most established relationships in cardiometabolic medicine. Because tirzepatide produces large weight loss (around 21% of body weight at the top dose in SURMOUNT-1), a good share of the blood-pressure drop travels with the weight coming off². That also implies the benefit is tied to staying on treatment and keeping the weight off; the blood-pressure gain is not a permanent "reset."

Direct incretin effects. Beyond weight, the GLP-1 and GIP pathways tirzepatide activates have their own actions on the cardiovascular system and kidneys — including effects on sodium handling and vascular tone — that plausibly contribute to lower blood pressure independent of pounds lost⁴. A 2025 review of blood-pressure effects across the GLP-1 and related drug classes puts tirzepatide's reduction in line with the broader class: a real, modest antihypertensive signal that rides alongside the metabolic benefits⁶.

The practical read: the blood-pressure drop is partly "because you lost weight" and partly "because of what the drug does" — and both parts depend on continued treatment.

The other direction: tirzepatide slightly raises heart rate

An honest blood-pressure page has to name the flip side. Like other drugs in its class, tirzepatide modestly increases heart rate. In the same ABPM substudy, 24-hour heart rate ticked up with tirzepatide versus placebo, and across the full SURMOUNT-1 population pulse rose by roughly 0.6 to 2.6 beats per minute at the higher doses, versus almost no change on placebo¹. This small pulse increase is a recognized class effect of incretin drugs and is generally considered clinically minor for most people⁴, but it is worth knowing — especially if you already have a heart-rhythm condition, in which case it is a conversation for your clinician. This is one of several cardiometabolic effects to weigh; for the broader safety picture, see the full Zepbound side effects breakdown.

The finding shows up in other tirzepatide trials, too

The blood-pressure signal is not unique to SURMOUNT-1. SURPASS-2, the head-to-head diabetes trial against semaglutide, showed tirzepatide driving larger reductions in weight and blood sugar than semaglutide⁵ — the kind of metabolic change that tends to pull blood pressure down, though that trial did not feature blood pressure as a reported endpoint. Where blood pressure was measured, the direction held: in SURMOUNT-OSA, the sleep-apnea trials that led to Zepbound's obstructive-sleep-apnea approval, systolic blood pressure was a prespecified secondary endpoint and fell with tirzepatide — notable because untreated sleep apnea is itself a driver of high blood pressure³. We cover that indication in Zepbound for sleep apnea. A 2025 review pooling blood-pressure effects across the GLP-1 and related drug classes likewise places tirzepatide's reduction in line with the broader class⁶, and a 2026 review pulling the cardiometabolic evidence together places these blood-pressure reductions within tirzepatide's wider "cardiovascular continuum" of effects on weight, glucose, kidney, and heart-failure endpoints⁷.

So the picture is consistent: in the obesity and sleep-apnea trials that actually measured it, tirzepatide moves blood pressure in the same favorable direction, in line with what the broader drug class shows.

What this does NOT mean

This is the part that matters most for safety.

• •Zepbound is not approved to treat high blood pressure. Its FDA label is for chronic weight management (and, for Zepbound specifically, obstructive sleep apnea in adults with obesity); Mounjaro's is for type 2 diabetes⁸⁹. Blood-pressure lowering is a documented effect, not an approved indication — no one should be prescribed tirzepatide for hypertension.
• •Do not stop or reduce your blood-pressure medication on your own. If you are on antihypertensives and start losing significant weight on tirzepatide, your blood pressure can fall enough that your existing medication becomes too strong — but any change to those drugs must be made by the prescriber who monitors you, not self-directed. Stopping blood-pressure medication abruptly can be dangerous.
• •A trial average is not your result. The 7-11 mm Hg figure is a group average in a specific trial population. Your own response depends on your starting blood pressure, how much weight you lose, your other medications, and your kidneys.

The bottom line

Does Zepbound lower blood pressure? On the evidence, yes: tirzepatide reduced 24-hour systolic blood pressure by roughly 7 to 11 mm Hg in SURMOUNT-1's rigorous ambulatory substudy, with a consistent signal in its sleep-apnea trial and across the broader drug class¹³⁶. That reduction is driven largely by the substantial weight loss the drug produces, with a probable direct incretin contribution on top — and it comes with a small, offsetting rise in heart rate¹⁴. But this is a favorable side effect of a weight-management drug, not a treatment for hypertension: Zepbound and Mounjaro are not approved for blood pressure, the trial population was largely normotensive, and no one should adjust their blood-pressure medication without their prescriber⁸⁹. For the full picture of what tirzepatide is and isn't proven to do, start with our tirzepatide evidence guide; to weigh how it stacks up against the other leading option, see tirzepatide vs semaglutide; and if you are comparing where and how to get it, our best tirzepatide providers overview lays out the options.